Certara, Inc. (NASDAQ:CERT) Shares Purchased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA raised its stake in Certara, Inc. (NASDAQ:CERT) by 40.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,901,898 shares of the company’s stock after buying an additional 1,128,006 shares during the period. Massachusetts Financial Services Co. MA owned approximately 2.42% of Certara worth $45,691,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its holdings in Certara by 1.6% in the 1st quarter. Russell Investments Group Ltd. now owns 77,753 shares of the company’s stock valued at $1,375,000 after purchasing an additional 1,191 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Certara by 6.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 58,899 shares of the company’s stock valued at $1,054,000 after acquiring an additional 3,639 shares during the last quarter. Silvercrest Asset Management Group LLC grew its position in Certara by 27.3% during the first quarter. Silvercrest Asset Management Group LLC now owns 516,300 shares of the company’s stock valued at $9,231,000 after acquiring an additional 110,636 shares during the period. Janus Henderson Group PLC increased its stake in Certara by 2.9% during the first quarter. Janus Henderson Group PLC now owns 127,399 shares of the company’s stock worth $2,279,000 after acquiring an additional 3,578 shares during the last quarter. Finally, Motley Fool Asset Management LLC raised its holdings in shares of Certara by 97.5% in the 1st quarter. Motley Fool Asset Management LLC now owns 98,566 shares of the company’s stock worth $1,762,000 after purchasing an additional 48,671 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This trade represents a 33.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at $552,503.73. The trade was a 9.75 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by company insiders.

Certara Stock Up 6.0 %

Shares of Certara stock opened at $10.36 on Monday. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of -51.80, a PEG ratio of 4.94 and a beta of 1.51. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.87. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The business’s 50 day simple moving average is $10.79 and its 200-day simple moving average is $13.17.

Certara (NASDAQ:CERT) last issued its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same period last year, the company earned $0.06 earnings per share. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. Equities research analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CERT has been the subject of a number of research reports. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a report on Friday, September 27th. Robert W. Baird dropped their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. Finally, Barclays reduced their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.